Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis.

MLA

Shinji Okabayashi, et al. “Individualized Treatment Based on CYP3A5 Single-Nucleotide Polymorphisms with Tacrolimus in Ulcerative Colitis.” Intestinal Research, vol. 17, no. 2, Apr. 2019, pp. 218–26. EBSCOhost, https://doi.org/10.5217/ir.2018.00117.

APA

Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, Osamu Takeuchi, & Toshifumi Hibi. (2019). Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intestinal Research, 17(2), 218–226. https://doi.org/10.5217/ir.2018.00117

Chicago

Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, et al. 2019. “Individualized Treatment Based on CYP3A5 Single-Nucleotide Polymorphisms with Tacrolimus in Ulcerative Colitis.” Intestinal Research 17 (2): 218–26. doi:10.5217/ir.2018.00117.